Company Overview
Avanos Medical, Inc. operates as a medical technology company that provides specialized medical device solutions across North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America, with a specific focus on digestive health products such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal devices. The company functions within the Healthcare sector and specifically within the Medical Devices industry, positioning it as a provider of essential infrastructure for patient care and clinical operations globally. Avanos Medical, Inc. currently maintains a market capitalization of $634.83M and generates annual revenue of $701.20M, employing a workforce of 2287 individuals to support its extensive product portfolio. These financial metrics indicate that the company holds a mid-cap valuation relative to the broader medical device landscape, suggesting a mature operational scale that is significant enough to fund global distribution networks while maintaining a substantial employee base.
Financial Health
The company reported revenue of $701.20M for the trailing twelve months, a net income of -$72,900,000, and an EBITDA of $54.40M, revealing a distinct gap between top-line revenue and bottom-line profit that highlights the substantial impact of operating expenses and other costs on the final earnings figure. Despite the reported net loss, the business generated free cash flow of $46.01M, which signifies a strong ability to generate liquidity from operations and provides the company with significant financial flexibility to fund ongoing research, development, or debt servicing without relying solely on external capital markets. The company's profitability margins demonstrate specific structural characteristics, with a gross margin of 50.5% indicating efficient production and pricing power, an operating margin of 2.0% reflecting high fixed cost sensitivity or aggressive spending, and a profit margin of -10.4% confirming that operating expenses exceed operating income at the current scale. In terms of balance sheet leverage, Avanos Medical, Inc. holds $89.80M in cash against $129.10M in debt, resulting in a debt-to-equity ratio of 16.59, which characterizes the balance sheet as highly leveraged given the significant debt load relative to equity. Liquidity is supported by a current ratio of 2.15, indicating that the company possesses more than twice the current assets necessary to cover its short-term obligations, thereby reducing immediate liquidity risk. Return metrics further illuminate management effectiveness, showing a return on equity of -9.1% and a return on assets of 0.9%, which reveals that the company is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns in the absence of significant earnings growth.
Valuation Assessment
Valuation multiples for Avanos Medical, Inc. present a complex picture, with a trailing P/E ratio of N/A due to negative earnings and a forward P/E of 10.92, implying that the market is pricing in a future trajectory where earnings are expected to turn positive or stabilize significantly to justify current share prices. The price-to-book ratio stands at 0.81, indicating that the market values the company's equity at a discount to its book value, which often suggests that the market perceives high risk or that the asset base may not be fully optimized for future cash generation. Alternative valuation metrics provide additional context, with a price-to-sales ratio of 0.91 and an EV/EBITDA of 12.39, suggesting that the company is trading at a premium relative to its sales compared to the forward P/E but remains below a traditional 1.0x multiple when considering enterprise value relative to earnings before interest, taxes, depreciation, and amortization. Price volatility is bounded by a 52-week high of $15.68 and a 52-week low of $9.30, meaning the current share price sits within a defined trading range that reflects recent market sentiment and sentiment shifts over the past year. The stock exhibits a beta of 1.09, which indicates that the stock's price volatility is slightly higher than the broader market, meaning it tends to amplify market movements rather than moving in perfect lockstep with the overall index.
Growth & Income
Growth metrics for Avanos Medical, Inc. show a revenue growth of 0.7% year-over-year and earnings growth of N/A, indicating that top-line revenue is expanding at a very slow pace while earnings are currently negative and therefore cannot be compared directly to prior periods for growth calculation. The company does not distribute dividends to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which implies that the firm reinvests all available cash flow into operations, debt reduction, or capital expenditure rather than returning capital via dividends. This non-dividend status is consistent with the company's negative net income and negative return on equity, as paying dividends would be financially unsustainable given the current earnings trajectory and high debt levels. Overall, the growth and income profile is characterized by modest revenue expansion in the digestive health sector coupled with a lack of current income generation, requiring investors to rely on potential future earnings turnaround rather than current yield or rapid growth rates.